Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study
Epilepsia · 2026
DOI: 10.1002/epi.70264 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia, 2026. Verfasst von Yutong Fu und 56 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Folic Acid, Epilepsy, Dietary Supplements, Anticonvulsants. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sichuan Province Science and Technology Support Program, Sichuan Provincial Science and Technology Support Program.
Abstract (Originalsprache)
Objective
Folic acid (FA) is essential for fetal development, while the benefits and optimal dose in pregnant women with epilepsy (PWWE) remain unclear. This study explores effects of FA supplementation, dose, and initiation time on offspring outcomes in PWWE.
Methods
This multi‐center cohort recruited PWWE from 58 hospitals in China. Anti‐seizure medication (ASM) and FA exposures were categorized by first‐trimester use. The primary outcome was a composite of preterm birth, low birth weight (LBW), major congenital anomalies (MCAs), fetal death, and neurodevelopmental delay. Logistic regression models assessed the associations between FA exposure, dose, initiation time, and adverse outcomes, adjusting for demographics and epilepsy characteristics, with stratification by maternal ASM use. Dose–response relationships were analyzed using restricted cubic splines.
Results
Among 1013 women with 1209 pregnancies, 952 received FA. In ASM‐exposed pregnancies, FA supplementation was associated with lower risks of composite adverse offspring outcomes (adjusted odds ratio [aOR] .59, 95% confidence interval [CI] .387–.911) and fetal death (aOR .127, 95% CI .054–.296), whereas no significant differences were observed between preconception and first‐trimester initiation. Compared to no supplement, supplementation with .4 mg/day protected against fetal death (aOR .185, 95% CI .078–.428); doses exceeding .4 mg/day further reduced risk of composite adverse outcomes (aOR .343, 95% CI .162–.675), and doses above 1 mg additionally showed trends toward decreased preterm birth in ASM‐exposed pregnancies (aOR .338, 95% CI .104–.943). Compared with .4 mg supplementation, doses above 1 mg/day were associated with a lower risk of LBW (aOR .208, 95% CI .05–.58). Significance FA supplementation was associated with lower risks of composite adverse offspring outcomes in ASM‐exposed pregnancies, specifically at doses exceeding .4 mg. No such associations were observed in pregnancies not exposed to ASMs. However, the optimal upper limit of high‐dose FA supplementation requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Sichuan Provincial Engineering Research Center of Brain-Machine Interactive Neuromodulation, Chengdu, Sichuan, China.
- Laboratory of Neuro-Diseases and Multimorbidity, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Sichuan Provincial Model Worker and Craftsman Innovation Studio, Chengdu, Sichuan, China.
- Department of Clinical Research and Management, Center of Biostatistics, Design, Measurement and Evaluation (CBDME), West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
ORCID-Profile: Yutong Fu, Fanfan Shi, Jiajia Fang, Yanbing Han, Hua Zhang, Yanmei Zhu, Lei Chen
Förderung
- Sichuan Province Science and Technology Support Program
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Fu, Y., Shi, F., Sha, L., Ma, Y., Lin, W., Li, X., Yan, H., Wang, P., Fang, J., Huang, Q., Chen, F., Li, Y., Kong, Q., Huang, H., Hu, X., Liu, C., Wang, J., Xiao, X., Zhang, Q., …, & Chen, L. (2026). Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study. Epilepsia. https://doi.org/10.1002/epi.70264
Vancouver
Fu Y, Shi F, Sha L, Ma Y, Lin W, Li X, et al. Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study. Epilepsia. 2026. doi:10.1002/epi.70264
BibTeX
@article{Fu2026,
author = {Fu, Yutong and Shi, Fanfan and Sha, Leihao and Ma, Ying and Lin, Weihong and Li, Xiaoyi and Yan, Hua and Wang, Pei and Fang, Jiajia and Huang, Qun and Chen, Fang and Li, Yun and Kong, Qingxia and Huang, Hua and Hu, Xiangshu and Liu, Changqing and Wang, Jian and Xiao, Xiaohua and Zhang, Qi and Mei, Rong and Han, Yanbing and Wu, Yuan and He, Shixu and Zhang, Hua and Wang, Kuiyun and Zhu, Yanmei and Lin, Wanhui and Peng, Zhanghui and Zhu, Xi and Wu, Xunyi and Yu, Ming and Zou, Mei and Zou, Xin and Wu, Ting and He, Xuelian and Guo, Haizhi and Zhong, Min and Zhang, Qing and Su, Yan and Liu, Yaqing and Feng, Qin and Wang, Houfen and Chen, Wenwu and Sun, Yanping and Sun, Meizhen and Zhou, Jian and Zhao, Hongjian and Guo, Chonglun and Gao, Jing and Guo, Yi and Huang, Jiajun and Sun, Hao and Luo, Xiaojing and Yang, Ruiqi and Qin, Huan and Tomson, Torbjörn and Chen, Lei},
title = {Folic acid supplementation and prevention of adverse offspring outcomes among women with epilepsy: An observational study},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70264}
}
EUVIMED